Mineralys Therapeutics (MLYS) Non Operating Income (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Non Operating Income of $6.0 million for Q1 2026, down 0.74% sequentially from $6.0 million in Q4 2025, and up 168.02% YoY from $2.2 million in Q1 2025.
Mineralys Therapeutics (MLYS) Non Operating Income (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Non Operating Income for 5 years, with the latest figure at $6.0 million in Q1 2026.
- Quarterly Non Operating Income rose 168.02% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.7 million (up 51.99% YoY) and the FY2025 annual result came in at $16.0 million, up 9.36% from the prior year.
- Non Operating Income declined to $6.0 million in Q1 2026 per MLYS's latest filing, from $6.0 million in the prior quarter.
- Over five years, Non Operating Income peaked at $6.0 million in Q4 2025 and troughed at $745000.0 in Q3 2022.
- A 5-year average of $3.4 million and a median of $3.5 million in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income surged 371.54% in 2023, then slumped 41.89% in 2025.
- Over 5 years, Non Operating Income stood at $935000.0 in 2022, then surged by 255.19% to $3.3 million in 2023, then retreated by 15.21% to $2.8 million in 2024, then surged by 114.7% to $6.0 million in 2025, then declined by 0.74% to $6.0 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $6.0 million, $6.0 million, and $4.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 4.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.97 Mn |
| Mar 31, 2026 | 6.00 Mn |
| Dec 31, 2025 | 6.05 Mn |
| Sep 30, 2025 | 4.20 Mn |
| Jun 30, 2025 | 3.47 Mn |
| Mar 31, 2025 | 2.24 Mn |
| Dec 31, 2024 | 2.82 Mn |
| Sep 30, 2024 | 3.76 Mn |
| Jun 30, 2024 | 4.15 Mn |
| Mar 31, 2024 | 3.85 Mn |
| Dec 31, 2023 | 3.32 Mn |
| Sep 30, 2023 | 3.51 Mn |
| Jun 30, 2023 | 3.59 Mn |
| Mar 31, 2023 | 2.33 Mn |
| Dec 31, 2022 | 935,000.00 |
| Sep 30, 2022 | 745,000.00 |